Suppr超能文献

2016 - 2021年印度儿童腹泻的患病率及治疗情况

Prevalence and Treatment of Diarrhea Among Children in India, 2016-2021.

作者信息

Jain Anoop, Kim Rockli, Subramanian S V

机构信息

Department of Environmental Health, Boston University School of Public Health, Boston, Massachusetts.

Division of Health Policy and Management, College of Health Science, Korea University, Seoul, South Korea.

出版信息

JAMA Netw Open. 2025 Aug 1;8(8):e2526979. doi: 10.1001/jamanetworkopen.2025.26979.

Abstract

IMPORTANCE

The World Health Organization recommends the use of oral rehydration solution (ORS) for the treatment of child diarrhea. In India, adherence to these guidelines remains far less than complete.

OBJECTIVE

To elucidate geographic variations in ORS treatment for child diarrhea between and within India's 720 districts.

DESIGN, SETTING, AND PARTICIPANTS: This repeated cross-sectional study used data from 2 rounds of India's National Family Health Survey from 2016 and 2021. Complete diarrhea data were available from 246 695 children in 2016 and 223 785 children in 2021 from all 720 districts in both waves. Data on ORS treatment were available for 22 413 children in 2016 and 15 302 children in 2021. These children lived in 716 of India's 720 districts in 2016 and in 718 districts in 2021. The data were analyzed in October 2024.

MAIN OUTCOMES AND MEASURES

The primary outcome was the district-level percentage of children who received ORS treatment if they had diarrhea in the past 2 weeks. The prevalence of diarrhea was also estimated. These values were estimated for both outcomes in 2016 and 2021 so that change over time could be estimated. The SD of the community-level prevalence of children who received ORS treatment by each district as a measure of the within-district inequality was also estimated for 2016 and 2021.

RESULTS

The study included 246 695 children younger than 5 years (mean [SD] age, 2.0 [1.4] years; 128 098 boys and 118 597 girls) for diarrhea prevalence and 22 413 children younger than 5 years (mean [SD] age, 1.5 [1.3] years; 12 050 boys and 10 363 girls) for ORS treatment in 2016. The study also included 223 785 children younger than 5 years (mean [SD] age, 2.0 [1.4] years; 115 632 boys and 108 153 girls) for diarrhea prevalence and 15 302 children younger than 5 years (mean [SD] age, 1.6 [1.4] years; 8160 boys and 7142 girls) for ORS treatment in 2021. Of the 9.2% (95% CI, 9.1%-9.3%) of children who had diarrhea in the 2 weeks prior to the survey in 2016, 50.6% (95% CI, 50.0%-51.3%) were treated with ORS. In 2021, 7.3% (95% CI, 7.2%-7.4%) of children had diarrhea, of whom 60.7% (95% CI, 59.9%-61.5%) were treated with ORS. There was considerable between-district variation in the prevalence of ORS treatment for child diarrhea (as of 2021, the state or Union Territory with the lowest district-level prevalence of ORS treatment was Haryana [49.0%]; the state or Union Territory with the highest district-level prevalence of ORS treatment was Jammu and Kashmir [83.4%]). The prevalence of ORS treatment decreased by more than 2.49 percentage points in 185 districts between 2016 and 2021 even though, nationally, the prevalence of ORS treatment increased over the same period, from a median of 57.5% (IQR, 47.2%-66.5%) to a median of 62.4% (IQR, 56.9%-72.5%). Finally, many districts with high prevalence of child diarrhea had low prevalence of ORS treatment. And in 71 districts, the prevalence of child diarrhea increased while the prevalence of ORS treatment decreased between 2016 and 2021.

CONCLUSIONS AND RELEVANCE

This cross-sectional study of the prevalence of child diarrhea and its treatment with ORS in India found that the prevalence of ORS treatment for child diarrhea increased at a national level between 2016 and 2021, but this increase was not even between or within India's 720 districts. The findings suggest that efforts aimed at promoting ORS treatment for child diarrhea in India must address the place-based factors that might be associated with underuse of this treatment.

摘要

重要性

世界卫生组织建议使用口服补液盐(ORS)治疗儿童腹泻。在印度,对这些指南的遵循程度仍远未达到完全遵循。

目的

阐明印度720个区之间以及区内儿童腹泻ORS治疗的地理差异。

设计、背景和参与者:这项重复横断面研究使用了来自印度2016年和2021年两轮全国家庭健康调查的数据。两轮调查中,来自所有720个区的2016年246695名儿童和2021年223785名儿童有完整的腹泻数据。2016年有22413名儿童和2021年有15302名儿童有ORS治疗的数据。这些儿童在2016年居住在印度720个区中的716个区,在2021年居住在718个区。数据于2024年10月进行分析。

主要结局和测量指标

主要结局是过去2周内腹泻儿童接受ORS治疗的区级百分比。还估计了腹泻患病率。对2016年和2021年这两个结局的这些值进行了估计,以便能够估计随时间的变化。还估计了2016年和2021年每个区接受ORS治疗儿童的社区水平患病率的标准差,作为区内不平等的一种衡量指标。

结果

该研究纳入了246695名5岁以下儿童(平均[标准差]年龄,2.0[1.4]岁;128098名男孩和118597名女孩)用于腹泻患病率分析,以及2016年22413名5岁以下儿童(平均[标准差]年龄,1.5[1.3]岁;12050名男孩和10363名女孩)用于ORS治疗分析。该研究还纳入了223785名5岁以下儿童(平均[标准差]年龄,2.0[1.4]岁;115632名男孩和108153名女孩)用于腹泻患病率分析,以及2021年15302名5岁以下儿童(平均[标准差]年龄,1.6[1.4]岁;8160名男孩和7142名女孩)用于ORS治疗分析。在2016年调查前2周内腹泻的儿童中,9.2%(95%CI,9.1%-9.3%)的儿童接受了ORS治疗,其中50.6%(95%CI,50.0%-51.3%)接受了ORS治疗。在2021年,7.3%(95%CI,7.2%-7.4%)的儿童腹泻,其中60.7%(95%CI,59.9%-61.5%)接受了ORS治疗。儿童腹泻ORS治疗的患病率在各区之间存在相当大的差异(截至2021年,ORS治疗区级患病率最低的邦或联邦属地是哈里亚纳邦[49.0%];ORS治疗区级患病率最高 的邦或联邦属地是查谟和克什米尔[83.4%])。2016年至2021年期间,185个区的ORS治疗患病率下降了超过2.49个百分点,尽管在全国范围内,同期ORS治疗的患病率有所上升,从中位数57.5%(IQR,47.2%-66.5%)升至中位数62.4%(IQR,56.9%-72.5%)。最后,许多儿童腹泻患病率高的区ORS治疗患病率低。并且在71个区,2016年至2021年期间儿童腹泻患病率上升而ORS治疗患病率下降。

结论和意义

这项关于印度儿童腹泻患病率及其ORS治疗的横断面研究发现,2016年至2021年期间,印度全国范围内儿童腹泻ORS治疗的患病率有所上升,但这种上升在印度720个区之间以及区内并不均衡。研究结果表明,在印度旨在促进儿童腹泻ORS治疗的努力必须解决可能与该治疗使用不足相关的基于地点的因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14f7/12355290/90c6403dcb79/jamanetwopen-e2526979-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验